Gairong Zhang

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Jian-Ming Xu, Yun Zhang, Ru Jia et al. · Clinical Cancer Research · 2018 · 533 citations

Pharmacy, Oncology, Pharmacology +16

Superior osteogenic capacity of different mesenchymal stem cells for bone tissue engineering

Yong Wen, Baoqi Jiang, Jun Cui et al. · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · 2012 · 52 citations

Engineering, Bioengineering, Biomedical Engineering +16

Hair mercury concentrations and associated factors in an electronic waste recycling area, Guiyu, China

Wenqing Ni, Yaowen Chen, Yue Huang et al. · Environmental Research · 2013 · 40 citations

Pharmacy, Environmental Sciences, Toxicology +16

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors

Huiping Li, Rongrui Liu, Bin Shao et al. · Chinese Journal of Cancer Research · 2020 · 37 citations · Full text

Medicine, Oncology, Pharmacology +11

Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial.

Jianming Xu, Yun Zhang, Ru Jia et al. · Journal of Clinical Oncology · 2018 · 24 citations

Medicine, Oncology, Pharmacology +17